May 4, 2022--Researched by Industrial Info Resources (Sugar Land, Texas)--North American life science capital construction expenditures will remain robust through the end of 2022. Fears of a recession, higher interest rates and regulatory concerns have not dampened the fiscal plans of this sector, and the outlook remains very optimistic. Lack of available laboratory space, reshoring and expansion of manufacturing, expanded use of automation and contract manufacturing organizations (CMOs) are all major drivers in this strategy. Industrial Info is tracking nearly 500 major capital projects worth $25.2 billion slated for kickoff in the U.S. during the remainder of 2022.
This Premium Article can be purchased individually or as part of a subscription
Subscription Type:
Articles related to this company
